Summit Therapeutics CEO Applauds UK Antibiotics Market Pilot
But Summit’s Product Ridinilazole Is Not Taking Part This Time
Executive Summary
The world hopes a UK pilot can offer guidance on making novel antibiotics commercially viable, Summit Therapeutics CEO tells Scrip, but adds his lead asset won’t take part this time.